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Chimeric antigen receptors (CARs) are artificial recombinant receptors that generally combine the antigen-recognition domain 
of a monoclonal antibody with T cell activation domains. Recent years have seen great success in clinical trials employing 
CD19-specific CAR-T cell therapy for B cell leukemia. Nevertheless, solid tumors remain a major challenge for CAR-T cell 
therapy. This review summarizes the preclinical and clinical studies on the treatment of solid tumors with CAR-T cells. The 
major hurdles for the success of CAR-T and the novel strategies to address these hurdles have also been described and dis-
cussed. 
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The concept of a chimeric antigen receptor (CAR) was first 
described by Kuwana and colleagues in 1987 (Diamond et al., 
2011). Since its introduction, remarkable improvements 
have been made to increase the specificity, persistence, and 
activity of CAR-T cells.  
CARs are broadly categorized into three generations. 
First-generation CARs mediate modified T cell activation 
via the CD3 zeta chain (CD3 signaling domain, leading to 
pro-inflamma- tory cytokine secretion, T cell proliferation, 
tumor cell lysis in vitro, and the eradication of transplanted 
tumors in in vivo mouse models. Clinical trials, however, 
have only shown modest efficacy of first-generation CARs. 
Incomplete T cell activation and lack of costimulation are 
thought to be the primary causes of the weak response in 
patients; tumors frequently do not provide ligands for cost-
imulatory molecules on T cells, and the signal through the 
CD3 chain alone is insufficient for priming resting T cells. 
Next, second-generation CARs contain costimulatory sig-
naling domains derived from T cell costimulatory, with re-
ceptors such as CD28 being the most common choice. 
CD28-mediated CAR signaling is preferred in inducing 
IL-2 secretion and promoting T cell amplification 
(Chmielewski et al., 2011). Besides CD28, other costimula-
tory molecules, such as tumor necrosis factor receptor su-
perfamily member 9 (TNFRSF9, 4-1BB), tumor necrosis 
factor receptor superfamily, member 4 (TNFRSF9, OX40), 
inducible T-cell CO Stimulator (ICOS), and CD27, may be 
included in CAR construction to take advantage of their 
associated functions in regulating T cell proliferation, sur-
vival, and antitumor response. In particular, 4-1BB costim-
ulation induces IL-2 and IFN- production and enhances 
CD8+ T-cell responses. Moreover, 4-1BB signaling seems 
to be essential for the persistence of the memory CD8+ T 
cells (Campana et al., 2014). By some researchers, 4-1BB 
costimulation is considered more effective than CD28 
costimulation, as the former reduces exhaustion induced by 
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persistent CAR signaling (Annenkov et al., 2002). Never-
theless, an advantage of CD28 signaling is the potential to 
circumvent CTLA-4 inhibition (Dubinski et al., 2015). Fi-
nally, third-generation CARs are constructed from two 
costimulatory molecular signaling regions. However, more 
evidence is needed to demonstrate the superiority of 
third-generation CAR-T cells over second-generation 
CAR-T cells.  
Recent results from clinical trials indicated that CAR-T 
therapy is remarkably successful in treating hematological 
malignancies (Davila et al., 2014; Kalos et al., 2011;  
Lee et al., 2014; Shannon et al., 2014; Maude et al., 2014). 
However, the benefits of CAR-T cell therapy on solid tu-
mors were far less clear. In this review, we will discuss the 
current progress in CAR-T cell therapy, including im-
provements to target antigen specificity, results from pre-
clinical and clinical studies, as well as novel strategies to 
increase the method’s safety and efficacy against solid tu-
mors. 
ANTIGEN CHOICE IN SOLID TUMORS 
Tumor antigens targeted by CAR-modified T cells could be 
cell surface proteins and glycolipids, carbohydrates, and 
sometimes the major histocompatibility complex 1 
(MHC-I). An ideal tumor antigen for CAR-T therapy should 
target only cancer cells, but few truly tumor-specific anti-
gens exist. Most antigen candidates for CAR-T cells are 
expressed in both tumor cells and some normal cells. Con-
sequently, the selection of tumor antigens requires balanc-
ing antitumor efficacy with the risk of “on-target, 
off-tumor” toxicity in normal tissue. Selecting an appropri-
ate target is a critical step to ensure CAR-T function, as 
evidenced by the extremely positive outcomes in CAR-T 
treatments of hematological malignancies, attributed in part 
to the choice of CD19, an ideal target widely expressed by 
acute lymphoblastic leukemia cells. While also found in 
normal cells, CD19 expression is restricted to B cells and 
their progenitors, allowing the use of gamma-globulin to 
protect the patients from infection. To date, more than 20 
antigens have been used as the targets of CAR-T cells for 
solid tumors (Table 1). In addition, neoantigens are emerg-
ing as possible biomarkers in cancer immunotherapy. 
Formed by peptides that are entirely absent from the normal 
human genome, their presence provides an incentive for 
developing neoantigen-specific CAR-T cells (Schumacher 
and Schreiber, 2015). 
Generally, CAR-T cells recognize and bind to targeted 
antigens via the single chain antibody expressed on the tar-
get cell surface. Thus, antigen intensity appears to be a fac-
tor that influences CAR-T cell function. Typically, CAR-T 
cells target highly expressed antigens while ignoring those 
that are lowly expressed (Usanarat Anurathapan et al., 
2013). This property, however, is a double-edged sword. An 
Table 1  Antigens targeted by CAR-T for the treatment of solid tumors 
Antigen Full name Cancer 
AC133  Glioblastoma (Liao et al., 2015) 
B7H6  Ovarian melanoma (Wu et al., 2015c) 
CAIX Carbonic anhydrase IX Metastatic renal cell carcinoma (Lamers et al., 2013) 
CEA Carcinoembryonic antigen pancreatic tumors (Chmielewski et al., 2012) 
CSPG4 Chondroitin sulfate proteoglycan-4 Melanoma, HNSCC, breast carcinoma (Geldres et al., 2013) 
EGFR Type III variant of the epidermal growth factor 
receptor 
Glioblastoma (Miao et al., 2014) 
EphA2 Erythropoietin-producing 
hepatocellular A2 
Lung cancer (Kakarla et al., 2013), 
glioblastoma (Chow et al., 2013) 
FAP Fibroblast activation protein Cancer-associated stromal cells (Yarden and Sliwkowski, 2001) 
Alpha FR Alpha folate receptor Ovarian cancer (Song et al., 2011) 
GD2 Disialoganglioside 2 Neuroblastoma (Craddock et al., 2010; Pule et al., 2008) 
GPC3 Glypican-3 Hepatocellular carcinoma (Gao et al., 2014) 
Her2 Human epidermal growth factor receptor 2 Ovarian cancer (Lanitis et al., 2012a), medulloblastoma (Ahmed et al., 2007) 
IL13Ra2 Interleukin-13Ra2 Glioblastoma (Krebs et al., 2014) 
L1-CAM (CD171) Adhesion molecule L1-CAM Neuroblastoma, medulloblastoma, ovarian adenocarcinoma (Hong et al., 
2014) 
LMP-1 Latent membrane protein 1 nasopharyngeal carcinoma (Tang et al., 2014) 
Mesothelin  Malignant pleural mesotheliomas (Beatty et al., 2014) 
MUC-1  Breast carcinoma (Wilkie et al., 2008) 
NKG2D Natural killer group 2 member D Ovarian cancer (Spear et al., 2013) 
PSMA Prostate specific membrane antigen Prostate cancer (Stephan et al., 2007) 
PSCA Prostate stem cell antigen Pancreatic cancer (Abate-Daga et al., 2014) 
TRAIL-receptor 1 TNF-related apoptosis-inducing ligand  
(TRAIL) receptor 1 
Colon cancer, ovarian cancer (Kobayashi et al., 2014) 
VEGFR-1 Vascular endothelial growth factor receptor-1 Neovascularization (Wang et al., 2013) 
EGFR Epidermal growth factor receptor Epithelial carcinoma, non-small cell lung cancer (Zhou et al., 2013) 
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advantage is the avoidance of on-target, off-tumor toxicity, 
as normal tissues often express low levels of tumor-    
associated antigens. However, a clear disadvantage is the 
failure of lowly expressed of antigens to fully activate 
CAR-T cells, which then cannot efficiently eliminate tumor 
cells with low densities of target antigens. 
PRECLINICAL STUDIES 
CAR-T cells targeting several tumor-associated antigens 
have been advanced into clinical trials. Here, we describe 
several preclinical studies on these target-redirected CAR-T 
cells.  
Her-2-specific CAR-T cells 
Human epidermal growth factor receptor 2 (Her-2, also 
called neu or ErbB2) is a member of the epidermal growth 
factor receptor (EGFR) family. It is one of the most com-
monly studied tumor-associated antigens for cancer immu-
notherapy, as it is widely expressed on medulloblastoma, 
osteosarcoma, glioblastoma, and breast cancer cells. Initial 
studies using N29, a first-generation CAR derived from 
Her2-specific scFv, demonstrated specificity and lysis ac-
tivity dependent on Her2 presence (Stancovski et al., 1993). 
Another such CAR (FRP5) resulted in sustained regression 
of established medulloblastomas in an orthotopic, xenoge-
neic mouse model (Ahmed et al., 2007). Subsequent data 
confirmed the functionality of second-generation (CD28) 
CARs expressing canine T cells on Her-2+ osteosarcoma 
(Mata et al., 2014). Further study revealed that CD28-  
modified second-generation CAR-T cells significantly in-
hibited tumor growth in mice bearing osteosarcoma or 
breast tumor xenografts (Sun et al., 2014). Taken together, 
these results highlight the clinical potential of Her-2 target-
ed CAR-T therapy. 
EGFRvIII-specific CAR-T cells 
The epidermal growth factor receptor variant III (EG-
FRvIII) is an oncogenic variant of EGFR, absent in normal 
tissue but exclusively expressed in tumors from several 
cancer types, including glioblastoma (GBM), breast cancer, 
and non-small cell lung cancer (NSCLC). Most EG-
FRvIII-redirected CAR-T studies were assessed in glio-
blastoma models. Early preclinical studies demonstrated the 
potential antitumor effect of first-generation CARs targeting 
EGFRvIII (González-Navajas et al., 2012; Jacoby et al., 
2015). Subsequent second- and third-generation CAR-T 
cells validated their antitumor activity on EGFRvIII+ glio-
blastoma cells. Furthermore, intracerebral injection of third- 
generation CAR-T cells successfully inhibited tumor growth 
(Choi et al., 2014). Intriguingly, after systemic delivery, 
EGFRvIII-targeted third-generation CAR-T cells could lo-
calize to intracranial tumors, suppress tumor growth, and 
enhance the survival of mice carrying established GBM 
xenografts (Miao et al., 2014). 
Mesothelin-specific CAR-T cells 
Mesothelin is a tumor-associated antigen that is overex-
pressed in many cancer types (e.g., malignant pleural mes-
otheliomas (MPM), pancreatic cancers, and ovarian can-
cers) and lowly expressed on normal peritoneal, pleural, as 
well as pericardial mesothelial surfaces (Beatty et al., 2014). 
Thus, immunotherapy that targets mesothelin has yielded 
promising results. For example, a recent study (Carpenito et al., 
2009) engineered T cells with high affinity for mesothelin 
(CD28-41BBz) and transferred them intratumorally or in-
travenously into immunodeficient mice, engrafted with tu-
mors pre-established by serial passage of primary pleural 
effusion cells from mesothelioma patients. As a result, the 
engineered T cells reduced the tumor burden and in some 
cases completely eradicated the tumors at low effec-
tor-to-target ratios (Carpenito et al., 2009). Similarly, intra-
tumoral injection of RNA CAR electroporated T cells me-
diated regression of large, vascularized flank-mesothelioma 
tumors in mice (Zhao et al., 2010), although these T cells 
are less potent in the same model than lentivirus-transduced 
T cells, which cure most mice (Carpenito et al., 2009). Fur-
thermore, adoptive transfer of mesothelin-targeted first- 
generation CAR-T cells mediated regression of ovarian 
cancer in a xenogeneic model (Lanitis et al., 2012b). These 
findings support the potent clinical application of meso-
thelin-specific CAR-T cells for MPM, ovarian cancer, and 
other solid tumors. 
GD2-specific CAR-T cells 
Ganglioside GD2 is a tumor-associated surface antigen 
found in a broad spectrum of human cancers and stem cells, 
including pediatric embryonal tumors and adult cancers. 
Because its distribution in normal tissue is restricted, GD2 
is safe for immunotherapy targeting (Krug et al., 2015). 
Third-generation CAR-T cells, based on GD2-specific an-
tibody sc14.G2a, secreted significant levels of cytokines 
upon antigen recognition and exhibited anti-melanoma ac-
tivity both in vitro and in xenograft models (Yvon et al., 
2009). Additionally, first-generation CAR-T cells co-   
expressing chemokine receptor CCR2b was constructed and 
improved homing, as well as greater anti-tumor activity, to 
CCL2-secreting GD2+ neuroblastoma in vivo was observed 
(Craddock et al., 2010). 
CEA-specific CAR-T cells  
CEA is a 180-kD tumor-associated glycoprotein. It is a 
well-known tumor-inducer that is overexpressed in many 
epithelial cancers, most notably in colorectal adenocarci-
noma and pancreatic tumors. A recent study reported rejec-
tion of carcinoembryonic antigen (CEA)-positive pancreatic 
tumors in CEA-transgenic mice that expressed CEA as self- 
antigen in healthy gastrointestinal cells (Chmielewski et al., 
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2012). Adoptive therapy with CEA-targeted first-generation 
CAR-T cells eliminated CEA+ tumors in a primary re-
sponse. Moreover, upon rechallenge, cured mice produced 
an efficient, long-term recall response towards CEA+ tumor 
cells. The antitumor response of CD28-costimulatory 
CAR-T cells was also validated in an animal model for 
CEA+ colorectal cancer (Emtage et al., 2008). 
EphA2-specific CAR-T cells 
EphA2 has emerged as an attractive target for GBM immu-
notherapy because it is overexpressed in glioma and pro-
motes malignancy. Studies found that EphA2 signaling 
plays an important role in glioma cell proliferation (Liu et al., 
2006), migration, and invasion (Miao et al., 2009). 
EphA2-specific CAR-T cells (CD28z) could recognize 
EphA2-positive glioma cells and were potent against human 
glioma-initiating cells, preventing neurosphere formation 
and destroying intact neurospheres in coculture assays. Ad-
ditionally, adoptive transfer of EphA2-specific CAR-T cells 
resulted in the regression of glioma xenografts in a mouse 
model (Chow et al., 2013). When combined with FAP (fi-
broblast activation protein)-specific T cells (CD28z), these 
EphA2 specific CAR-T cells significantly enhanced overall 
antitumor activity and conferred a survival advantage over 
either treatment alone (Kakarla et al., 2013). 
NK cell activating receptor-based CAR-T cells 
It is well known that NK cells employ activating receptors, 
such as NKG2D, NKp30, and DNAX accessory molecule-1 
(DNAM-1), to recognize stress-induced ligands expressed 
on various tumor types. Therefore, CARs composed of the 
ligand-binding region of these receptors or the scFv against 
these ligands were developed and the resulted CAR-T cells 
have been evaluated in preclinical animal models, with en-
couraging antitumor results (Wu et al., 2015b, 2015c; 
Zhang et al., 2012). However, sometimes lethal toxicity was 
observed (VanSeggelen et al., 2015). 
Beside these commonly used targets, many other anti-
gens are emerging as potential CAR-T targets in solid tu-
mors. For example, we demonstrated that GPC3 is a suita-
ble antigen for the development of CAR-T cells to treat 
hepatocellular carcinoma (Gao et al., 2014) and lung squa-
mous non-small cell lung cancer (Li K, et al., 2015). Other 
research has shown that interleukin-13Ra2 specific CAR-T 
cells may be used to eliminate glioblastoma (Krebs et al., 
2014). In general, existing preclinical data strongly indicate 
that CAR-T cells are extremely robust antitumor reagents. 
CLINICAL TRIALS 
To date, about 40 clinical trials using CAR-T to treat solid 
tumors have been performed (Table 2). These clinical trials 
include first-, second-, and third-generation CAR-T cells. 
First-generation CAR-T cells 
As early as 2006, Kershaw et al. conducted a phase I clini-
cal trial using CAR-T cells to target the ovarian can-
cer-associated antigen, -folate receptor (FR) (Kershaw et al., 
2006). However, tumor burden was not reduced in any pa-
tient after infusion with first-generation CAR-T. In the same 
year, Lamers et al. reported another clinical trial that treated 
metastatic clear cell renal cell carcinoma (RCC) using  
carboxy-anhydrase-IX (CAIX)-targeted CAR-T cells 
(Lamers et al., 2006). An unexpected liver toxicity was ob-
served, caused by the CAR-T cells attacking the CAIX+ bile 
duct epithelial cells. This study demonstrated that CAR-T 
cells redirected to targets shared by normal and cancer cells 
would cause on-target off-tumor toxicity. Thus, to reduce 
such risks, additional safety mechanisms must be incorpo-
rated into these CARs to reduce the risk. However, another 
clinical trial using first-generation CAR-T cells targeting 
L1-cell adhesion molecule (L1-CAM) also showed no sig-
nificant toxicities and toxicities and limited efficacy when 
treating six children with recurrent/refractory neuroblasto-
ma (Park et al., 2007). Besides on-target off-tumor side ef-
fects, infused CAR-T cells may be immunogenic because of 
the associated transgene and the retroviral vector-encoded 
epitopes (Lamers et al., 2011). Thus. it is essential to atten-
uate the immunogenicity of both transgene and vector.  
Generally, the first-generation CAR-T cells do not sur-
vive well in vivo. Therefore, Epstein-Bar virus (EBV)-  
specific CTLs were engineered to express a chimeric anti-
gen receptor directed at the disialoganglioside GD2, a tu-
mor-associated antigen expressed by human neuroblastoma 
cells (Pule et al., 2008). They found that virus-specific 
CAR-T cells persisted in higher numbers and for longer 
periods after infusion to patients than CAR-T cells that lack 
EBV specificity (Pule et al., 2008). The characteristics as-
sociated with virus-specific CAR-T cells were linked to 
subsequent tumor necrosis or sustained complete remission. 
Thus, virus-specific CAR-T cells may offer distinct ad-
vantages as tumor- directed effector cells.  
Second- and third-generation CAR-T cells 
Several second- and third-generation CAR-T cells have 
advanced into clinical trials. As one example, a phase I/II 
clinical study was conducted in which patients with recur-
rent/refractory sarcoma received escalating doses of T cells 
expressing an Her2-specific chimeric antigen receptor, with 
a CD28-CD3 signaling domain (Ahmed et al., 2015). Alt-
hough the second-generation Her2-CAR-T cells persisted 
for six weeks in patients without evident toxicity, the clini-
cal outcome was limited. Third-generation CARs specific to 
Her2 was also tested in clinical trials. However, these CARs 
caused lethal on-target, off-tumor toxicity in a patient with 
colon cancer (Morgan et al., 2010). This serious side effect 
prompted researchers to modify CAR-T cells with a “safety 
switch” to limit toxicity. Such switches include caspase-9   
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Table 2  Summary of CAR-T clinical trials in solid tumorsa) 
Number Antigen Disease CAR generation Phase Clinicaltrials.gov identifier
1 CAI Clear cell renal, cell carcinoma   NCT00602862 
2 CD171 Neuroblastoma, ganglioneuroblastoma Second/Third (41BB/CD28-41BB) I NCT02311621 
3 CEA Adenocarcinoma  I NCT00004178 
4 CEA Colorectal carcinoma Second (CD28) I NCT00673322 
5 CEA Breast cancer Second (CD28) I NCT00673829 
6 CEA Solid tumor  I NCT01212887 
7 CEA Liver metastases Second (CD28) I NCT01373047 
8 CEA Adenocarcinomas Second (CD28) II NCT01723306 
9 CEA CEA+ solid tumors  I NCT02349724 
10 EGFRvIII Glioblastoma Third 
(CD28-41BB) 
I/II NCT01454596 
11 EGFRvIII Glioblastoma  I NCT02209376 
12 EGFR EGFR positive advanced solid tumors Second (41BB) I/II NCT01869166 
13 EGFR Advanced glioma  I NCT02331693 
14 FAP Malignant pleural mesothelioma  I NCT01722149 
15 FR Ovarian cancer  I NCT00019136 
16 GD2 Neuroblastoma First I NCT00085930 
17 GD2 Neuroblastoma  I NCT01460901 
18 GD2 Neuroblastoma Third (CD28-OX40) I NCT01822652 
19 GD2 Osteosarcoma Third (CD28-OX40) I NCT01953900 
20 GD2 Non-neuroblastoma, GD2+ solid tumors Third (CD28-41BB) I NCT02107963 
21 GD2 Neuroblastoma Third (CD28-OX40) I NCT02439788 
22 GPC3 Hepatocellular carcinoma  I NCT02395250 
23 Her2 Lung malignancy Second (CD28) I NCT00889954 
24 Her2 Advanced osteosarcoma Second (CD28) I NCT00902044 
25 Her2 Metastasized Her2+ cancer Third (CD28-41BB) I NCT00924287 
26 Her2 GBM Second (CD28) I NCT01109095 
27 Her2 Solid tumors First and second (4-1BB) I/II NCT01935843 
28 Her2 Her2 positive malignancy  I NCT00889954 
29 IL 13 zetakine  Brain and CNS tumors  I NCT00730613 
30 IL13R2 Glioma, neoplasm Second (4-1BB) I NCT02208362 
31 Mesothelin Pancreatic cancer Second (4-1BB) I NCT02465983 
32 Mesothelin Pancreatic (ductal) adenocarcinoma,  
ovarian cancer, mesothelioma 
Second (4-1BB) I NCT02159716 
33 Mesothelin   I NCT02388828 
34 PSMA Prostate cancer First I NCT00664196 
35 PSMA Prostate cancer Second (CD28) I NCT01140373 
36 ErbB Head and neck cancer Second (CD28) I NCT01818323 
a) From https://www.clinicaltrials.gov/. 
(Gargett and Brown, 2014), caspase-8 (Khaleghi et al., 
2012), Herpes simplex thymidine kinase (Hsv-tk) (Jensen et 
al., 2010), and CD20 suicide genes (Burnette et al., 2011). 
Recently, six patients (with chemotherapy-refractory meta-
static pancreatic ductal adenocarcinoma) were treated with 
autologous T cells, transiently expressing a meso-
thelin-specific CAR that includes both CD3 and 4-1BB 
costimulatory domains (Beatty et al., 2015). Of the admin-
istered CAR-T cell infusions, 98% showed no dose-limiting 
toxicity. Infusions were well tolerated, without evidence of 
cytokine release syndrome, pleuropericarditis, or peritonitis. 
Two of the six patients were categorized as experiencing 
stable disease under RECIST 1.1 guidelines, and in one 
patient, liver metastases were no longer detected after ther-
apy. These outcomes suggest that the CARmeso T cells 
successfully exhibited antitumor activity. Additionally, T 
cells bearing bispecific CAR were also applied to treat pa-
tients with progressive Her2+ GBM (Nabil et al., 2015). 
Only one out of fifteen patients exhibited partial response 
and four patients had stable disease after CAR-T infusion. 
Overall, the results of clinical trials have demonstrated 
that CAR-T cells do exhibit antitumor activity in humans. 
However, clinical responses to CAR-T cell treatment of 
solid tumors are generally far from satisfactory. Therefore, 
considerable effort must still be made to increase the safety 
and efficacy of CAR-T cell therapy. 
NOVEL STRATEGIES TO INCREASE THE 
SAFETY AND EFFICACY OF CAR-T  
The difference in the clinical responses between solid tu-
mors and blood cancers, especially leukemia, is very obvi-
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ous. There are at least four important reasons for this great 
difference. The first reason is that CAR-T cells cannot easi-
ly penetrate solid tumor tissues to fight the cancer. The 
second reason is that a solid tumor represents an extremely 
hostile microenvironment that hampers the infiltration, ex-
pansion, survival of the CAR-T cells, because tumor-   
educated immune cells, mesenchymal cells, and vascular 
endothelial cells are present along with tumor cells. The 
third reason is that cancer cells and the target antigens in the 
solid tumor are generally heterogeneous, which negatively 
affects CAR-T cell antitumor activities. The fourth reason is 
that cancer-specific antigens in solid tumor are very limited. 
All of these problems contribute to on-target off-tumor tox-
icity, which undeniably limits the therapeutic window of 
CAR-T cells. Thus, considerable effort is being exerted to 
develop a variety of strategies aimed at improving the safety 
and efficacy of CAR-T cell therapy. 
Enhanced accumulation of CAR-T cells into the tumor 
tissues 
Several strategies have been designed to increase CAR-T 
cell migration to the tumor site. One strategy is to engineer 
T cells with chemokine receptors. For instance, Kershaw et 
al. showed that deficiencies in T cell chemotaxis towards 
tumor cells are overcome by transgenic CXCR2 expression, 
facilitating the recognition of tumor-produced Gro- 
(Kershaw et al., 2002). Likewise, results from murine 
xenograft experiments demonstrated that overexpression of 
the chemokine receptor CCR4 by CD30-specific CAR-T 
cells  enhances their migration into Hodgkin’s lymphoma 
(Di Stasi et al., 2009). Moreover, CCR2b-modified CAR-T 
cells redirected to GD2 have improved tumor-specific traf-
ficking and significantly enhanced activity against neuro-
blastoma xenografts (Craddock et al., 2010).  
Although chemokine receptor modification improves 
CAR-T cell migration to tumor sites, it does little to pro-
mote cell extravasation, necessary for eventual contact be-
tween the effector cells and the target tumor cells. To solve 
this issue, one study incorporated echistatin into CAR-T 
cells (Fu et al., 2013). Echistatin binds strongly to ν3 
integrin, which is highly expressed on the surface of endo-
thelial cells from tumor neovasculature. The echistat-
in-modified CAR-T was then able to lyse human umbilical 
vein endothelial cells and tumor cells that express ν3 
efficiently in vitro. Additionally, systemic administration of 
echistatin-modified CAR-T cells led to extensive bleeding 
in tumor tissues with no evidence of damage to blood ves-
sels in normal tissues.  
Recently, CAR-T cells were found to lose heparanase 
(HPSE) expression after in vitro culture. Heparanase de-
grades heparin sulfate proteoglycans, the main components 
of the extracellular matrix. Thus, re-expression of HSPE in 
CAR-T cells significantly improved their T cell infiltration 
and antitumor activities (Caruana et al., 2015). Another 
method of improving CAR-T penetration into tumors is the 
use of cancer-associated fibroblasts (CAF). Specifically, a 
recent finding revealed that FAP-specific CAR-T cells, ca-
pable of destroying FAP-positive fibroblast cells, could in-
crease the antitumor activity of EphA2-targeted CAR-T 
cells in lung cancer models (Kakarla et al., 2013). 
Armored cytokines to increase immune response 
Most immunotherapy trials yield primarily transient tumor 
regression, likely because we tend to neglect the heteroge-
neity of tumor lesions at the immunologic level. CAR-T 
cells themselves are not able to lyse target-negative tumor 
cells directly. Therefore, it seems necessary to equip CAR-T 
cells with cytokines such as IL-12, which play a pivotal role 
in immunoregulatory functions. To mediate tumor lysis, 
IL-12 can augment the activation of cytotoxic T cells and 
NK cells, both primary effectors of the adaptive and innate 
immune responses. A recent study has demonstrated the 
effectiveness of this method; CEA-specific CAR-T cells, 
carrying an NFAT6-induced IL-12 transgene, were able to 
eradicate mixed CEA-positive and CEA-negative tumor 
cells (Watford et al., 2003). 
Optimization of costimulatory signals 
Although CD28 and 4-1BB are the most commonly used 
costimulatory molecules, less conventional options, such as 
MyD88 and CD40, may ultimately prove to be more suita-
ble for CAR-T cell immunotherapy. In a recent report, 
MyD88/CD40 was able to promote higher levels of IL2 
production in CAR-T cells than CD28 (Lasek et al., 2014). 
CAR-T cells bearing MYD88/CD40 signals also display 
enhanced efficacy in CD19+ and Her2+ tumor models, re-
spectively, compared with CAR-T cells bearing the CD28 
signal. Costimulation with MYD88 or CD40 resulted in 
greater T cell proliferation, cytokine production, and anti-
tumor efficacy in vivo than control CARs with standard 
costimulatory molecules. Similarly, CD40L-modified 
CAR-T (CD28-CD3) exhibited more antitumor activity in 
a xenotransplant model of CD19+ systemic lymphoma than 
CD28-CD3 cells without CD40L (Curran et al., 2015). 
Finally, T lymphocytes armed with the uncommonly used 
CD80 and 4-1BBL provoked potent rejection of large, sys-
temic tumors in a xenotransplant model of PSMA+ prostate 
cancer (Stephan et al., 2007). 
Regional delivery of CAR-T cells 
Taking advantage of an orthotopic model that faithfully 
mimics human pleural malignancy, Adusumilli et al. used 
M28z CAR to evaluate two routes of mesothelin-targeted T 
cell administration (Adusumilli et al., 2014). They found 
that intrapleurally administered CAR-T cells vastly outper-
formed systemically infused T cells, requiring 30-fold fewer 
M28z T cells to induce long-term, complete remission. Af-
ter intrapleural T cell administration, prompt in vivo anti-
gen-induced T cell activation allowed robust CAR-T cell 
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expansion and effector differentiation, resulting in enhanced 
antitumor efficacy and functional T cell persistence for 200 
days. Regional T cell administration also promoted the effi-
cient elimination of extrathoracic tumor sites. The ability of 
intrapleurally administered T cells to circulate and persist 
within the periphery opens new avenues of treatment for 
metastatic cancers with accessible tumor sites, which may 
serve as “regional charging and distribution centers” for 
CAR-T cell therapy. Appropriate candidates include cancers 
that metastasize to the pleural cavity, such as lung and 
breast cancers, as well as those that metastasize to the peri-
toneal cavity, such as pancreatic and ovarian cancers. In 
addition to intrapleural or intraperitoneal administration, 
Choi et al. implanted EGFRvIII CAR-T cells intracerebrally 
and successfully treated glioma in mice (Choi et al., 2014). 
At the very least, this approach may decrease the T cell 
dose requirement, presenting an advantage when high 
numbers of CAR-T cells are not attainable (i.e., due to 
low-yield apheresis, poor ex vivo expansion, or low trans-
duction). In the best case, regional delivery may even obvi-
ate the need for systematic apheresis. 
Increasing the safety index of CARs 
The importance of successfully redirecting CAR-T cells to 
cancer tissues and away from normal tissues cannot be 
overestimated, because doing so reduces toxicity and in-
creases the therapeutic window. However, as stated previ-
ously, cancer-specific antigens like EGFRvIII are very rare. 
Therefore, numerous strategies have been developed to in-
crease the safety of CAR-T cell therapy. One popular and 
clinically tested method of controlling CAR-T cells in vivo 
is to include suicide switches in the vectors used to engineer 
T cells. For instance, the caspase switch efficiently elimi-
nates T cells in patients (Di Stasi et al., 2011; Russo et al., 
2012), and the “tumor sensing” approach, which combines 
two types of antigen recognition with balanced signaling, 
can potentially reduce on-target off-tumor toxicity (Kloss et al., 
2013). Yet another way to circumvent on-target off-tumor 
toxicity is the recently developed antigen-specific inhibitory 
chimeric antigen receptors (iCARs) technology (Fedorov et al., 
2013). The iCAR has a surface antigen recognition domain 
combined with a powerful acute inhibitory signaling do-
main to limit T cell responsiveness despite engagement of 
an activating receptor. This study demonstrated that 
CTLA-4- or PD-1-based iCAR could temporarily and selec-
tively limit cytotoxicity induced through the endogenous T 
cell receptor or an activating chimeric receptor.  
Promising methods to increase the therapeutic window 
include TanCAR, which mediates bispecific activation and 
targeting of T cells. This novel receptor produces synergis-
tic enhancement of effector functions when encountering 
two antigens and preserves cytolytic ability upon the loss of 
one target (Grada et al., 2013). In addition, fine-tuning 
CAR-T cell affinities may increase their therapeutic index, 
as low-affinity CAR-T cells appear capable of discriminat-
ing tumor cells with high EGFR or Her2 expression from 
tumors with low expression (Caruso et al., 2015; Liu et al., 
2015).  
Combination with immune checkpoint inhibitors 
The expression and activity of immune checkpoints signifi-
cantly affect the survival and function of the CAR-T cells. 
Thus, a potential method of increasing CAR-T cell activity 
is a combination with immune checkpoint inhibitors. For 
instance, adding an anti-PDL1 antibody significantly re-
stored the killing activity of CAR-T cells (Moon et al., 
2014). Notably, anti-CTLA-4 and anti-PD-1 antibodies have 
shown clinical promise by derepressing anti-T cell respons-
es in some patients with melanoma, lung, and renal cancer 
(Carosella et al., 2015). However, researchers have not fully 
explored the efficacy of joint therapeutic techniques in-
volving both CAR-T cells and immunomodulatory agents 
such as the anti CTLA-4 or PD-1 checkpoint inhibitors.  
FUTURE DIRECTIONS AND CONCLUDING 
REMARKS 
In this review, we summarized the current preclinical and 
clinical studies on CAR-T therapy against solid tumors. 
Although the results of clinical studies have thus far yielded 
limited achievements, we are confident in the potential of 
solid tumor treatments using CAR-T. We should bear in 
mind that CAR-T is completely different from other current 
antitumor therapies, including antibodies and small-   
molecule drugs. There is tremendous scope for increasing 
CAR-T cell efficacy and safety, but this cannot be achieved 
without further clinical trials to validate treatment and tailor 
them to patients appropriately. Moreover, CAR-T cells are 
amenable to combinations with other therapy options. For 
example, low dose irradiation may be used to promote 
CAR-T infiltration into tumor tissues (Wu et al., 2015a). In 
conclusion, we believe that with increased effort and atten-
tion, CAR-T cells will soon become a potent and efficient 
treatment method for solid tumors. 
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